Menu Search
Equities

EZZ Life Science Holdings Ltd

EZZ:ASX

EZZ Life Science Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)2.90
  • Today's Change-0.22 / -7.05%
  • Shares traded285.37k
  • 1 Year change+360.32%
  • Beta0.4767
Data delayed at least 20 minutes, as of Sep 20 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year EZZ Life Science Holdings Ltd grew revenues 78.88% from 37.14m to 66.44m while net income improved 91.87% from 3.63m to 6.96m.
Gross margin76.67%
Net profit margin10.48%
Operating margin17.98%
Return on assets32.25%
Return on equity38.79%
Return on investment38.61%
More ▼

Cash flow in AUDView more

In 2024, EZZ Life Science Holdings Ltd increased its cash reserves by 37.54%, or 5.19m. The company earned 6.14m from its operations for a Cash Flow Margin of 9.25%. In addition the company used 441.17k on investing activities and also paid 582.45k in financing cash flows.
Cash flow per share0.1707
Price/Cash flow per share17.51
Book value per share0.4801
Tangible book value per share0.4797
More ▼

Balance sheet in AUDView more

EZZ Life Science Holdings Ltd has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 19.02m.
Current ratio5.96
Quick ratio5.63
Total debt/total equity0.0058
Total debt/total capital0.0058
More ▼

Growth rates in AUD

Year on year, growth in earnings per share excluding extraordinary items increased 90.18%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)0.99%
Div growth rate (5 year)--
Payout ratio (TTM)9.20%
EPS growth(5 years)52.48
EPS (TTM) vs
TTM 1 year ago		89.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.